id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-1650-0003,FDA,FDA-2020-P-1650,"Determination That DOBUTREX (Dobutamine Hydrochloride), Equivalent 12.5 Milligram Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2020-12-21T05:00:00Z,2020,12,2020-12-21T05:00:00Z,,2020-12-21T13:53:01Z,2020-28080,0,0,09000064849aefda
FDA-2020-P-1650-0004,FDA,FDA-2020-P-1650,Final Response to Citizen Petition from FDA CDER to Cardinal Health Regulatory Sciences,Other,Response(s),2020-12-21T05:00:00Z,2020,12,2020-12-21T05:00:00Z,,2020-12-21T18:07:05Z,,0,0,09000064849b0d44
FDA-2020-P-1650-0002,FDA,FDA-2020-P-1650,Acknowledgment Letter from FDA DMS to Cardinal Health Regulatory Sciences,Other,Acknowledgement Letter/Receipt,2020-07-10T04:00:00Z,2020,7,2020-07-10T04:00:00Z,,2020-07-10T16:59:29Z,,0,0,090000648473bc28
FDA-2020-P-1650-0001,FDA,FDA-2020-P-1650,Citizen Petition from Cardinal Health Regulatory Sciences,Other,Citizen Petition,2020-07-10T04:00:00Z,2020,7,2020-07-10T04:00:00Z,,2024-11-06T23:37:45Z,,1,0,090000648473bb1d